![Sample our Bioscience journals, sign in here to start your access, Latest two full volumes FREE to you for 14 days]({"type":"image" , "src" : "/sda/5925/TOC-Subject-Sample-2021-Bioscience.jpg"})
Abstract
“Pharmaceutical manufacturers should be allowed to demonstrate bioequivalence in man, if their products fail to comply with arbitary in-vitro tests”, said Professor J.6. Wagner (Upjohn Center for Clinical Pharmacology, U.S.A.) at the opening address of the British Pharmaceutical Technology Conference, held at the London Tara Hotel from the 9th to 11th April. Professor Wagner was reviewing some of the more interesting aspects of 22 bioavailability studies which he has been involved in over the last 17 years.